Publications by authors named "G Pantaleo"

Article Synopsis
  • The study identifies biomarkers that can differentiate between immune-related cytokine release syndrome (irCRS) and sepsis in oncology patients undergoing immune checkpoint inhibitor therapy.
  • The analysis revealed that hepatocyte growth factor (HGF) and ferritin are particularly effective in predicting outcomes related to irHLH and Grade 3 irCRS, with a 100% positive and negative predictive value.
  • Patients with severe irCRS who did not respond to corticosteroids showed complete resolution after treatment with tocilizumab (TCZ), highlighting the potential for targeted therapies in these cases.
View Article and Find Full Text PDF

Background: Ideally, vaccination should induce protective long-lived humoral and cellular immunity. Current licensed COVID-19 mRNA vaccines focused on the spike (S) region induce neutralizing antibodies that rapidly wane.

Methods: Herein, we show that a subunit vaccine (CD40.

View Article and Find Full Text PDF

Herein, we present a paper that attempts to bridge the gap between CO oxidation catalytic tests performed in a model stream and a more realistic exhaust gas stream by incorporating characterization methods that allow for active probing of the catalyst surface. The results have shown that it is not just the abundance of a given type of species on the surface that impacts the activity of a system but also the ease of extraction of ions from their surface (time-of-flight secondary ion mass spectrometry) and the response of the support to change in the feed composition (dynamic in situ X-ray diffraction (XRD) with variable atmosphere). The study utilizes the method of doping a catalyst (RuO/CZ) with a small amount of alkali-metal (K or Na) carbonates in order to slightly modify its surface to gain insight into parameters that may cause discrepancies between model stream activity and complex stream activity.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated the effectiveness of tocilizumab (TCZ) for treating arthritis caused by immune checkpoint inhibitors (ICI-AR) and preventing relapses during ICI treatment reassignment.
  • Researchers analyzed data from 26 patients, finding that all patients treated with TCZ had significant improvement in their arthritis symptoms and many achieved remission without steroids after 24 weeks.
  • The results indicated that using TCZ as a preventive measure during ICI rechallenge significantly reduced relapse rates and extended ICI treatment duration compared to patients not receiving TCZ.
View Article and Find Full Text PDF